Friday 6 November 2026
Export TFX’s income statement to Excel — free account
Teleflex Incorporated
TFX Healthcare Medical Instruments & Supplies
Teleflex Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 17.2% from fiscal 2024.
- Revenue
- +0.15%
- EPS
- +342.0%
- Free cash flow
- +220.1%
- Total debt
- −39.4%
Quarter to September 2026, against a year earlier
151.46
0.69
−0.45%
Follow TFX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.04 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.30 | 2.45 | 2.49 | 2.73 | |
P/FCF ratio |
36.34 | 103.95 | 29.65 | 3,766.02 | |
P/Operating CF |
53.88 | 60.09 | 113.45 | (147.10) | |
P/B ratio |
1.79 | 1.90 | 1.72 | 1.74 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.83 | 3.56 | 3.57 | 3.87 | |
EV/EBITDA |
24.89 | 31.34 | 29.13 | 25.63 | |
EV/Operating CF |
32.23 | 62.12 | 28.32 | 79.73 | |
EV/FCF |
44.67 | 151.15 | 42.57 | 5,330.95 | |
Quick Ratio |
0.88 | 0.92 | 0.93 | 0.95 | |
Current Ratio |
2.01 | 2.60 | 2.55 | 2.54 | |
Net Debt/EBITDA |
0.00 | 20.20 | 30.61 | (30.04) | |
Debt/Assets |
25.50% | 41.37% | 38.59% | 38.02% | |
Debt/Equity |
0.46 | 0.97 | 0.85 | 0.85 | |
Asset Turnover |
0.32 | 0.32 | 0.31 | 0.28 | |
Operating CF/Net income |
0.10 | 0.92 | (5.72) | 0.00 | |
Capex/Depreciation |
(0.41) | (0.27) | (0.34) | 0.00 | |
Interest Coverage |
4.97 | 2.61 | 0.78 | 12.80 | |
Research and Development Expense of Revenue |
7.57% | 7.91% | 8.10% | 6.29% | |
Selling, General and Administrative Expense of Revenue |
38.87% | 37.44% | 41.22% | 26.01% | |
Intangible Assets out of Total Assets |
0.58 | 0.55 | 0.56 | 0.55 | |
Share Based Compensation of Revenue |
1.10% | 0.95% | 1.23% | 0.51% | |
Graham Net Nets |
(0.19) | (0.36) | (0.35) | (0.35) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
6.65% | (18.37%) | (19.06%) | (16.83%) | |
Free Cash Flow Yield |
2.75% | 0.96% | 3.37% | 0.03% | |
Revenue per Share |
13.69 | 13.09 | 12.39 | 12.75 | |
Operating CF per Share |
2.32 | 2.11 | 1.05 | 0.00 | |
Capex per Share |
(0.52) | (0.32) | (0.42) | (0.01) | |
Free Cash Flow per Share |
1.80 | 1.79 | 0.63 | (0.01) | |
Cash per Share |
10.38 | 6.89 | 6.99 | 8.48 | |
Shareholders Equity per Share |
84.22 | 66.68 | 69.69 | 70.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
84.22 | 66.68 | 69.69 | 70.03 | |
Free Cash Flow |
74.66 | 77.86 | 27.87 | (0.65) | |
Working Capital |
927.57 | 1,155.50 | 1,131.62 | 1,176.31 | |
Capital Expenditures |
(21.61) | (14.03) | (18.79) | (0.65) | |
Net Current Asset Value |
(1,009.47) | (2,006.37) | (1,838.90) | (1,884.13) | |
EV/EBIT |
11.41 | 180.68 | 121.13 | 65.12 | |
Capex to Sales |
0.04 | 0.02 | 0.03 | 0.00 | |
Price to Operating Income |
9.28 | 124.25 | 84.35 | 46.00 | |
| Other line items | |||||
Average Receivables |
486.15 | 439.21 | 415.02 | 286.16 | |
Average Payables |
154.39 | 150.43 | 143.33 | 114.03 | |
Average Inventory |
593.44 | 522.80 | 512.42 | 355.58 | |
Average Assets |
7,109.90 | 7,081.00 | 6,973.15 | 7,022.58 | |
Average Common Equity |
— | 3,573.70 | 3,589.80 | 3,701.45 |
Columns are period end dates · fundamentals updated 6 Nov 2026